Exact Sciences ( (EXAS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Exact Sciences Corp.’s stock has been on the rise following the announcement of impressive preliminary fourth-quarter revenue results, which exceeded market expectations. This success is largely attributed to strong sales in its Screening segment, particularly ColoGuard, and growth in Precision Oncology. Additionally, the company’s plans to launch new cancer tests in 2025, such as Cologuard Plus and Oncodetect, have bolstered investor confidence. Analysts have responded by maintaining or raising their price targets, while increased insider buying further underscores the positive sentiment around the stock.
More about Exact Sciences
YTD Price Performance: -0.75%
Average Trading Volume: 2,402,224
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $10.46B
For further insights into EXAS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.